Company Profile

Amarantus Bioscienceholdingsotcqbambsis A Biotechnology Company Developing Treatments And Diagnostics For Diseases In Theareas Of Neurologyregenerativemedicineand Orphan Diseasesambs Owns Therights To Engineered Skin Substituteprograma Regenerativemedicinebased Approach For Treating Severeburns With Full Thickness Autologous Skin Grown In Tissuecultureess Is Entering Phase2 Clinical Studies Under A Crada Agreement With Theus Armyand Is Also Preparing A Pivotal Development Program For Rarepediatric Diseasegiant Congenital Melanocytic Neviambs Aealso Has Licensing Rights To Eltoprazinea Phase2B Ready Small Moleculeindicated For Parkinson S Diseaselevodopa Induced Dyskinesiaadult Adhd And Alzheimer S Aggressionand Owns Theintellectual Property Rights To A Therapeutic Protein Known As Mesencephalic Astrocytederived Neurotrophic Factor And Is Developing Manf Based Products As Treatments For Brain And Ophthalmic Disordersambs Aediagnostics Division Owns Therights To Msprecisea A Proprietary Next Generation Dna Sequencingngsassay For Theidentification Of Patients With Relapsing Remitting Multiplesclerosisrrmsat First Clinical Presentationhas An Exclusiveworldwidelicenseto Thelymphocyteproliferation Testlympro Testa For Alzheimer S Diseasewhich Was Developed By Profthomas Arendtph D From Theuniversity Of Leipzigand Owns Intellectual Property For Thediagnosis Of Parkinson S Diseasenuropro Ambs Also Owns Thediscovery Of Neurotrophic Factorsphenoguarda Cthat Led To Manf S Discovery Amarantus Is A Founding Member Of Global Brain Health Coalitiongbhc Thegbhc Mission Is To Becometheleading Global Voicefor Brain Health Awareness And Empowerment By Converging Scienceclinical Research And Impactthecompany Believes That Tbi Induced Neurodegeneration Represents A New Frontier Of Clinical Research Which May Ultimately Allow For Commonalities Between Chronic Degenerativedisorders